Colorectal cancer is the second most deadly cancer, after lung cancer, killing 53,200 Americans annually.

Existing treatments for this type of cancer are not effective.

Given that late stage patients who fail chemotherapy have no meaningful treatment options, resulting in poor survival rates, BreakBio believes it has developed a treatment protocol that will show substantial improvement over existing therapy, increasing the likelihood that the FDA will award us “BREAKTHROUGH DESIGNATION”.

Achieving a BREAKTHROUGH to help these patients survive longer, and hopefully be cured, is our mission.